Clinical Trial Update: Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

An update on a phase 1/2 clinical trial evaluating liposomal annamycin in patients with refractory or relapsed acute lymphoblastic leukemia, sponsored by Callis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Liposomal Annamycin (annamycin liposome)

Snippet

Sponsor: Callisto Pharmaceuticals | Conditions: Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN